Intervet's Bird Flu Vaccine Receives EU License
Boxmeer, The Netherlands (ots/PRNewswire) - Intervet, a leadinganimal health company, received approval for its bird flu (avianinfluenza) vaccine Nobilis(R) Influenza H7N1. As a result, Europe nowhas a licensed vaccine to protect birds against the H7 field strain.Last year the European Commission approved Nobilis(R) Influenza H5N2.With the registration Intervet confirms its leading position in AIvaccines (including H5N2, H5N6, H7N1, H7N7 and H9N2) to protectchickens and ducks against different strains of bird flu.
The CVMP (Committee for Medicinal Products for Veterinary use)highlighted the fact that the current concerns about avian influenzahave mainly focused on H5 strains, but that the danger posed by H7strains should not be ignored. The world has been suffering from H7outbreaks for seven years. The Netherlands (2003) and Italy(1999-2000) already reported infections of H7 avian influenza.Similar to H5N1, birds with the H7 avian influenza virus can infecthumans, as has been demonstrated in the Netherlands in 2003. Theoutbreaks resulted in 30 millions birds being culled in theNetherlands, and 13 millions birds in Italy.
Paul van Aarle, Director Institutional Sales at Intervet said: "Itis necessary to be prepared for potential outbreaks caused by the H7virus. Therefore Intervet developed this product and applied forEuropean registration. Fortunately the CVMP/EMEA took the sameposition and reviewed the vaccine under the accelerated registrationprocedure. This is an excellent example of how industry andregulators can take their joint responsibility towards society."
The vaccine protects against the different varieties of the highlypathogenic H7 field strain. If embedded in national control programs,vaccination contributes substantially to controlling bird flu andreducing the circulation of the virus in the bird population. Byreducing the amount of virus in the field, the chance on infection ofpeople is reduced.
The vaccine contains inactivated virus, and has to be injected inorder to get a full immune response. Intervet research isinvestigating the possibilities for a new vaccine type for massapplication avoiding injection.
It is important to differentiate between infected and vaccinatedanimals. Birds vaccinated with H7N1 produce a different set ofantibodies than those birds infected with other variants of the H7field strain. These antibodies can be monitored using specificdiagnostic tests.
With a growing list of countries already using Nobilis(R)Influenza successfully in official governmental avian flu controlprograms, Intervet has accumulated a wealth of experience in the useof vaccines against bird flu. The company has been working withnational governments and international organizations to advise onoutbreak control and management as well as vaccination strategiesaimed at helping bring avian influenza to a halt. Information onthese strategies is available on: www.avian-influenza.com.
Note for the Editor
Intervet, a business unit of Akzo Nobel, based in Boxmeer, theNetherlands, with sales of EUR 1,125 million in 2006, is dedicated toresearch and development, production and marketing of innovativeanimal health products. Intervet's product range for use inlivestock, companion animals, poultry and fish includes vaccines,antiparasitics, anti-infectives, endocrine products, otherpharmaceutical specialties. Intervet operates globally with its ownmarketing organizations. The company currently employs around 5,300people.
Akzo Nobel is a Fortune Global 500 company and is listed on boththe Euronext Amsterdam and NASDAQ stock exchanges. It is alsoincluded on the Dow Jones Sustainability Indexes and FTSE4Good Index.Based in the Netherlands, we are a multicultural organization servingcustomers throughout the world with coatings, chemicals and human andanimal healthcare products. We employ around 62,000 people andconduct our activities in these four segments, with operatingsubsidiaries in more than 80 countries. Consolidated revenues for2006 totaled EUR 13.7 billion. The financial results for the secondquarter will be published on July 24, 2007.
Safe Harbor Statement(x)
This press release may contain statements which address such keyissues as Akzo Nobel's growth strategy, future financial results,market positions, product development, pharmaceutical products in thepipeline, and product approvals. Such statements should be carefullyconsidered, and it should be understood that many factors could causeforecasted and actual results to differ from these statements. Thesefactors include, but are not limited to, price fluctuations, currencyfluctuations, progress of drug development, clinical testing andregulatory approval, developments in raw material and personnelcosts, pensions, physical and environmental risks, legal issues, andlegislative, fiscal, and other regulatory measures. Statedcompetitive positions are based on management estimates supported byinformation provided by specialized external agencies. For a morecomprehensive discussion of the risk factors affecting our businessplease see our Annual Report on Form 20-F filed with the UnitedStates Securities and Exchange Commission, a copy of which can befound on the company's corporate website www.akzonobel.com. The 2006Annual Report on Form 20-F will be available at the end of the secondquarter of 2007.
(x) Pursuant to the U.S. Private Securities Litigation Reform Act1995.
ots Originaltext: IntervetIm Internet recherchierbar: http://www.presseportal.de
Contact:Not for publication - for more information: Suzanne Hendriksen, Tel: +31-(0)485-58-7893; Media Relations Officer, Fax: +31-(0)485-58-5392;Intervet International bv, email@example.com
In Zusammenarbeit mit Medizinfuchs
Intervet's Bird Flu Vaccine Receives EU License